The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Kouri, Fotini M ^a   Jensen, Samuel A ^a   Stegh, Alexander H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; PROTEIN BCL 2; PROTEIN BCL 2 LIKE 12; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

CANCER GROWTH; DRUG TARGETING; GLIOBLASTOMA; HUMAN; NONHUMAN; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE; BRAIN TUMOR; CELL NUCLEUS; GLIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CASPASES; CELL NUCLEUS; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84858142877     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/838916     Document Type: Review

References (62)

1. Kleihues P., Louis D. N., Scheithauer B. W., Rorke L. B., Reifenberger G., Burger P. C., Cavenee W. K., The WHO classification of tumors of the nervous system Journal of Neuropathology and Experimental Neurology 2002 61 3 215 225 (Pubitemid 34212595)
2. Wen P. Y., Kesari S., Malignant gliomas in adults The New England Journal of Medicine 2008 359 5 492 507
3. Hotchkiss R. S., Strasser A., McDunn J. E., Swanson P. E., Mechanisms of disease: cell death The New England Journal of Medicine 2009 361 16 1570 1583
4. Andrews G. A., Xi S., Pomerantz R. G., Lin C. J., Gooding W. E., Wentzel A. L., Wu L., Sidransky D., Grandis J. R., Mutation of P53 in head and neck squamous cell carcinoma correlates with BCL-2 expression and increased susceptibility to cisplatin-induced apoptosis Head and Neck 2004 26 10 870 877 (Pubitemid 39299306)
5. Ikegaki N., Katsumata M., Minna J., Tsujimoto Y., Expression of bcl-2 in small cell lung carcinoma cells Cancer Research 1994 54 1 6 8 (Pubitemid 24042076)
6. Monni O., Joensuu H., Franssila K., Klefstrom J., Alitalo K., Knuutila S., BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma Blood 1997 90 3 1168 1174 (Pubitemid 27314153)
7. Peter M. E., Krammer P. H., The CD95(APO-1/Fas) DISC and beyond Cell Death and Differentiation 2003 10 1 26 35 (Pubitemid 36511830)
8. Youle R. J., Strasser A., The BCL-2 protein family: opposing activities that mediate cell death Nature Reviews Molecular Cell Biology 2008 9 1 47 59
9. Gavathiotis E., Reyna D. E., Davis M. L., Bird G. H., Walensky L. D., BH3-triggered structural reorganization drives the activation of proapoptotic BAX Molecular Cell 2010 40 3 481 492
10. Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S., Wang X., Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade Cell 1997 91 4 479 489 (Pubitemid 27508237)
11. Ekert P. G., Vaux D. L., The mitochondrial death squad: hardened killers or innocent bystanders? Current Opinion in Cell Biology 2005 17 6 626 630 (Pubitemid 41540412)
12. Strik H., Deininger M., Streffer J., Grote E., Wickboldt J., Dichgans J., Weller M., Meyermann R., BCL-1 family protein expression in initial and recurrent glioblastomas: modulation by chemotherapy Journal of Neurology Neurosurgery and Psychiatry 1999 67 6 763 768
13. Doucette T., Yang Y., Zhang W., Fuller G. N., Suki D., Fults D. W., Rao G., Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma International Journal of Cancer 2011 129 9 2093 2103
14. Fels C., Schfer C., Hppe B., Bahn H., Heidecke V., Kramm C. M., Lautenschlger C., Rainov N. G., Bcl-2 expression in higher-grade human glioma: a clinical and experimental study Journal of Neuro-Oncology 2000 48 3 207 216
15. McDonald F. E., Ironside J. W., Gregor A., Wyatt B. B., Stewart M., Rye R., Adams J., Potts H. W. W., The prognostic influence of bcl-2 in malignant glioma British Journal of Cancer 2002 86 12 1899 1904
16. Krajewski S., Krajewska M., Ehrmann J., Sikorska M., Lach B., Chatten J., Reed J. C., Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin American Journal of Pathology 1997 150 3 805 814 (Pubitemid 27106152)
17. Huang D. C. S., O'Reilly L. A., Strasser A., Cory S., The anti-apoptosis function of: Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry EMBO Journal 1997 16 15 4628 4638 (Pubitemid 27326600)
18. Lin B., Kolluri S. K., Lin F., Liu W., Han Y. H., Cao X., Dawson M. I., Reed J. C., Zhang X. K., Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3 Cell 2004 116 4 527 540 (Pubitemid 38264430)
19. Lewis J., Oyler G. A., Ueno K., Fannjiang Y. R., Chau B. N., Vornov J., Korsmeyer S. J., Zou S., Hardwick J. M., Inhibition of virus-induced neuronal apoptosis by Bax Nature Medicine 1999 5 7 832 835 (Pubitemid 29318620)
20. Fannjiang Y., Kim C. H., Huganir R. L., Zou S., Lindsten T., Thompson C. B., Mito T., Traystman R. J., Larsen T., Griffin D. E., Mandir A. S., Dawson T. M., Dike S., Sappington A. L., Kerr D. A., Jonas E. A., Kaczmarek L. K., Hardwick J. M., BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development Developmental Cell 2003 4 4 575 585 (Pubitemid 36437563)
21. Kamer I., Sarig R., Zaltsman Y., Niv H., Oberkovitz G., Regev L., Haimovich G., Lerenthal Y., Marcellus R. C., Gross A., Proapoptotic BID is an ATM effector in the DNA-damage response Cell 2005 122 4 593 603 (Pubitemid 41191157)
22. Zinkel S. S., Hurov K. E., Ong C., Abtahi F. M., Gross A., Korsmeyer S. J., A role for proapoptotic BID in the DNA-damage response Cell 2005 122 4 579 591 (Pubitemid 41191156)
23. Nagane M., Levitzki A., Gazit A., Cavenee W. K., Huang H. J. S., Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases Proceedings of the National Academy of Sciences of the United States of America 1998 95 10 5724 5729
24. Zhu H., Cao X., Ali-Osman F., Keir S., Lo H. W., EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity Cancer Letters 2010 294 1 101 110
25. Konishi J., Yi F., Chen X., Vo H., Carbone D. P., Dang T. P., Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim Oncogene 2010 29 4 589 596
26. Li Z., Zhou S., Zhang L., Su C., Hang J., Zhao Y., Su B., Zhou C., BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer Medical Oncology 2011 28 572 577
27. Deng J., Shimamura T., Perera S., Carlson N. E., Cai D., Shapiro G. I., Wong K. K., Letai A., Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion Cancer Research 2007 67 24 11867 11875
28. Cragg M. S., Kuroda J., Puthalakath H., Huang D. C. S., Strasser A., Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Medicine 2007 4 10 1681 1690 (Pubitemid 350035457)
29. Costa D. B., Halmos B., Kumar A., Schumer S. T., Huberman M. S., Boggon T. J., Tenen D. G., Kobayashi S., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Medicine 2007 4 10 1669 1680 (Pubitemid 350035456)
30. Quadros M. R., Connelly S., Kari C., Abrams M. T., Wickstrom E., Rodeck U., EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC- activities Cancer Biology and Therapy 2006 5 5 498 504 (Pubitemid 43765284)
31. Stegh A. H., Kim H., Bachoo R. M., Forloney K. L., Zhang J., Schulze H., Park K., Hannon G. J., Yuan J., Louis D. N., DePinho R. A., Chin L., Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma Genes and Development 2007 21 1 98 111 (Pubitemid 46089711)
32. Scorilas A., Kyriakopoulou L., Yousef G. M., Ashworth L. K., Kwamie A., Diamandis E. P., Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family Genomics 2001 72 2 217 221 (Pubitemid 32242963)
33. Stegh A. H., Kesari S., Mahoney J. E., Jenq H. T., Forloney K. L., Protopopov A., Louis D. N., Chin L., DePinho R. A., Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma Proceedings of the National Academy of Sciences of the United States of America 2008 105 31 10703 10708
34. Stegh A. H., Chin L., Louis D. N., DePinho R. A., What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator Cell Cycle 2008 7 18 2833 2839
35. Zong W. X., Thompson C. B., Necrotic death as a cell fate Genes and Development 2006 20 1 1 15 (Pubitemid 43042662)
36. Stegh A. H., Brennan C., Mahoney J. A., Forloney K. L., Jenq H. T., Luciano J. P., Protopopov A., Chin L., DePinho R. A., Glioma oncoprotein Bc12L12 inhibits the p53 tumor suppressor Genes and Development 2010 24 19 2194 2204
37. Stegh A. H., DePinho R. A., Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma Cell Cycle 2011 10 1 33 38
38. Phillips H. S., Kharbanda S., Chen R., Forrest W. F., Soriano R. H., Wu T. D., Misra A., Nigro J. M., Colman H., Soroceanu L., Williams P. M., Modrusan Z., Feuerstein B. G., Aldape K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 3 157 173 (Pubitemid 43357943)
39. Verhaak R. G. W., Hoadley K. A., Purdom E., Wang V., Qi Y., Wilkerson M. D., Miller C. R., Ding L., Golub T., Mesirov J. P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B. A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H. S., Hodgson J. G., James C. D., Sarkaria J. N., Brennan C., Kahn A., Spellman P. T., Wilson R. K., Speed T. P., Gray J. W., Meyerson M., Getz G., Perou C. M., Hayes D. N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010 17 1 98 110
40. Tagscherer K. E., Fassl A., Campos B., Farhadi M., Kraemer A., Bck B. C., Macher-Goeppinger S., Radlwimmer B., Wiestler O. D., Herold-Mende C., Roth W., Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins Oncogene 2008 27 52 6646 6656
41. Manero F., Gautier F., Gallenne T., Cauquil N., Grée D., Cartron P. F., Geneste O., Grée R., Vallette F. M., Juin P., The small organic compound HA14-1 prevents Bcl-2 interaction with bax to sensitize malignant glioma cells to induction of cell death Cancer Research 2006 66 5 2757 2764
42. Dodou K., Anderson R. J., Small D. A. P., Groundwater P. W., Investigations of gossypol: past and present developments Expert Opinion on Investigational Drugs 2005 14 11 1419 1434 (Pubitemid 41601456)
43. Bushunow P., Reidenberg M. M., Wasenko J., Winfield J., Lorenzo B., Lemke S., Himpler B., Corona R., Coyle T., Gossypol treatment of recurrent adult malignant gliomas Journal of Neuro-Oncology 1999 43 1 79 86 (Pubitemid 29351981)
44. Fischer U., Schulze-Osthoff K., New approaches and therapeutics targeting apoptosis in disease Pharmacological Reviews 2005 57 2 187 215 (Pubitemid 41043884)
45. Horiguchi A., Asano T., Kuroda K., Sato A., Asakuma J., Ito K., Hayakawa M., Sumitomo M., Asano T., STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma British Journal of Cancer 2010 102 11 1592 1599
46. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y., A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Oncogene 2007 26 17 2435 2444 (Pubitemid 46597261)
47. Kong L. Y., Wu A. S., Doucette T., Wei J., Priebe W., Fuller G. N., Qiao W., Sawaya R., Rao G., Heimberger A. B., Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses Clinical Cancer Research 2010 16 23 5722 5733
48. Walensky L. D., Pitter K., Morash J., Oh K. J., Barbuto S., Fisher J., Smith E., Verdine G. L., Korsmeyer S. J., A stapled BID BH3 helix directly binds and activates BAX Molecular Cell 2006 24 2 199 210 (Pubitemid 44557124)
49. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 2 281 297
50. Xu J., Liao X., Wong C., Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG International Journal of Cancer 2010 126 4 1029 1035
51. Shi L., Chen J., Yang J., Pan T., Zhang S., Wang Z., MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity Brain Research 2010 1352 255 264
52. Naumann U., Schmidt F., Wick W., Frank B., Weit S., Gillissen B., Daniel P., Weller M., Adenoviral natural born killer gene therapy for malignant glioma Human Gene Therapy 2003 14 13 1235 1246 (Pubitemid 37034573)
53. Vogelbaum M. A., Tong J. X., Perugu R., Gutmann D. H., Rich K. M., Overexpression of bax in human glioma cell lines Journal of Neurosurgery 1999 91 3 483 489 (Pubitemid 29404442)
54. Streffer J. R., Rimner A., Rieger J., Naumann U., Rodemann H. P., Weller M., BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells Journal of Neuro-Oncology 2002 56 1 43 49 (Pubitemid 34256617)
55. Kelly P. N., Strasser A., The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy Cell Death and Differentiation 2011 18 9 1414 1424
56. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D. M., Vernetti L. A., Fesik S. W., Shen Y., Seed analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 Oncogene 2007 26 27 3972 3979 (Pubitemid 46884293)
57. Zhu C. J., Li Y. B., Wong M. C., Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells Journal of Neuroscience Research 2003 74 1 60 66 (Pubitemid 37176667)
58. Agrawal A., Min D. H., Singh N., Zhu H., Birjiniuk A., Von Maltzahn G., Harris T. J., Xing D., Woolfenden S. D., Sharp P. A., Charest A., Bhatia S., Functional delivery of siRNA in mice using dendriworms ACS Nano 2009 3 9 2495 2504
59. Ding H., Inoue S., Ljubimov A. V., Patil R., Portilla-Arias J., Hu J., Konda B., Wawrowsky K. A., Fujita M., Karabalin N., Sasaki T., Black K. L., Holler E., Ljubimova J. Y., Inhibition of brain tumor growth by intravenous poly ( -L-malic acid) nanobioconjugate with pH-dependent drug release Proceedings of the National Academy of Sciences of the United States of America 2010 107 42 18143 18148. Corrected in: Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19603, 2010
60. Das S., Srikanth M., Kessler J. A., Cancer stem cells and glioma Nature Clinical Practice Neurology 2008 4 8 427 435
61. Sheng Z., Li L., Zhu L. J., Smith T. W., Demers A., Ross A. H., Moser R. P., Green M. R., A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications Nature Medicine 2010 16 6 671 677
62. Danial N. N., Gimenez-Cassina A., Tondera D., Homeostatic functions of BCL-2 proteins beyond apoptosis Advances in Experimental Medicine and Biology 2010 687 1 32